A Phase 1 interventional study of Bexagliflozin in Type 2 Diabetes Mellitus, sponsored by Theracos. Withdrawn at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-30.
Sponsored by Theracos · Phase 1, Interventional, and Treatment
The purpose of this study is to determine the absolute bioavailability of bexagliflozin following a single oral dose co-administered with an intravenous dose.
Exclusion Criteria:
Each subject will receive a single oral dose of bexagliflozin tablets, 20 mg, followed by a single IV dosing of \< 30 ug 14C-bexagliflozin in 0.9% saline solution).
Drug: Bexagliflozin
Bexagliflozin tablets, 20 mg, and bexagliflozin by IV
Also known as: EGT0001442, EGT0001474
absolute bioavailability (Fp.o.) of bexagliflozin tablets
oral to IV ratio of dose-normalized AUC0-inf (area under the plasma concentration time curve extrapolated to infinity)
Time frame: Up to 48 hours
adverse events
adverse event as a measure of safety and tolerability of treatment
Time frame: Up to 3 days
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Theracos